Table 4.
List of C. albicans ‘omics datasets with a brief description of methodology. (Abbreviations: FCZ, fluconazole; MCN, miconazole; KCZ, ketoconazole; CSP, caspofungin and AmB, amphotericin B.)
| Citation | Species | Analysis | Strain | Drug | Methods details |
|---|---|---|---|---|---|
| Liu et al. (2005) | C. albicans | Transcriptomics (Microarray) | SC5314 | KCZ, 19.13 µg/mL | OD600 ∼0.2, 30°C SD, 3 h, n = 3 |
| AmB, 0.029 µg/mL | |||||
| CSP, 0.0075 µg/mL | |||||
| 5-FC, 0.098 µg/mL | |||||
| Vasicek et al. (2014) | C. albicans | Transcriptomics (Microarray) | SC5314 | FCZ, 10 µg/mL | OD600 ∼0.05, 30°C YPD, 6 h, n = 2 |
| Keller et al. (2015) | C. albicans | Transcriptomics (Microarray) | SC5314 | FCZ, ∼0.5 µg/mL (IC50) | OD600 ∼0.4, 30°C RPMI + 10% fetal calf serum, 3 h, n = 3 |
| de Cremer et al. (2016) | C. albicans | Transcriptomics (RNA-Seq) | SC5314 | MCN, 75 µM | Pre-formed biofilms +/− drug at 37°C in RPMI, 4 + 24 h, n = 3 |
| Shivarathri et al. (2019) | C. albicans | Transcriptomics (RNA-Seq) | SC5314 | CSP, 10 ng/mL | 30°C YPD, 15 + 45 min, n = 3 |
| Kuloyo et al. (2020) | C. albicans | Transcriptomics (RNA-Seq) | SC5314 | FCZ, 1 µg/mL | RPMI 37°C, adhered to polystyrene 90 min, +/− drug 6 h, n = 3 |
| Hoehamer et al. (2010) | C. albicans | Proteomics (MALDI-ToF) | SC5314 | KCZ, 19.13 µg/mL | OD600 ∼0.2, 30°C SD, 6 h, n = 3 |
| AmB, 0.029 µg/mL | |||||
| CSP, 0.0075 µg/mL | |||||
| Sorgo et al. (2011) | C. albicans | Proteomics (LC-ESI-MS/MS) | SC5314 | FCZ, 0.5 µg/mL | OD600 ∼0.05, 37°C YNB-S, 18 h, n = 5 |
| Ene et al. (2012) | C. albicans | Proteomics (LC-MS/MS) | RM1000 | Ambisome, 10 µg/mL | OD600 ∼0.1, YNB + 2% glucose or lactate, 1 h, n = 3 |
| CSP, 0.08 µg/mL | |||||
| MCN, 25 µg/mL | |||||
| Katragkou et al. (2016) | C. albicans | Metabolomics (GC-MS, UHPLC-Q-TOF/MS and HILIC-QQQ/MS) | SC5314 | KCZ, 16 µg/mL | FCZ sensitive and resistant (64 µg/mL) strains, 30°C YPD to 108 cells/mL, n = 6 |